Table 1 Characteristics of included case–control studies
First author, year [refs.] | NOS | Country/race | AA/AG/GG (case) | Cancer type | AA/AG/GG (control) | Control source | Genotyping method |
|---|---|---|---|---|---|---|---|
Abbasi, 2009 [23] | 8 | Germany/Caucasian | 30/109/107 | Laryngeal cancer | 72/281/291 | PB | Real-time PCR |
Akhmadishina, 2014 [24] | 8 | Russia/Caucasian | 39/53/43 | BC (Russian) | 28/68/48 | PB | PCR-RFLP |
Russia/Caucasian | 18/35/23 | BC (Tatar) | 35/67/32 | PB | PCR-RFLP | ||
Russia/Caucasian | 7/16/3 | BC (Bashkir) | 22/35/13 | PB | PCR-RFLP | ||
Russia/Caucasian | 9/23/21 | RCC (Russian) | 28/68/48 | PB | PCR-RFLP | ||
Russia/Caucasian | 7/20/13 | RCC (Tatar) | 35/67/32 | PB | PCR–RFLP | ||
Russia/Caucasian | 3/5/4 | RCC (Bashkir) | 22/35/13 | PB | PCR–RFLP | ||
Applebaum, 2007 [25] | 8 | USA/Caucasian | 95/345/428 | skin BCC | 101/325/347 | PB | Taqman |
USA/Caucasian | 72/268/322 | skin SCC | 101/325/347 | PB | Taqman | ||
Bau, 2007 [26] | 7 | China/Asian | 38/84/32 | oral cancer | 29/53/23 | HB | PCR-RFLP |
Butkiewicz, 2004 [8] | 7 | Germany/Caucasian | 23/94/93 | LSCC | 46/213/198 | HB | Melting curves/PCR-RFLP |
Chen, 2016 [27] | 8 | China/Asian | 41/39/28 | endometrial Cancer | 35/45/30 | PB | PCR-RFLP |
Crew, 2007 [28] | 7 | USA/Caucasian | 105/466/488 | Breast cancer | 137/477/488 | PB | Taqman |
De, 2007 [10] | 8 | Belgium/Caucasian | 10/54/46 | Lung cancer | 10/54/45 | PB | PCR-RFLP |
Ding, 2016 [29] | 8 | China/Asian | 44/66/20 | Breast cancer | 56/88/44 | PB | PCR-RFLP |
Ding, 2014 [30] | 7 | China/Asian | 201/268/137 | Breast cancer | 157/299/177 | HB | PCR-LDR |
Doherty, 2011 [31] | 6 | USA/Mixed | 67/297/339 | Endometrial Cancer | 66/320/328 | PB | SNPlex/SNaPshot |
Dong, 2008 [32] | 9 | China/Asian | 86/120/47 | GCA | 162/322/128 | PB | PCR-RFLP |
Feng, 2008 [33] | 7 | China/Asian | 85/83/28 | Esophageal cancer | 54/91/56 | HB | PCR-RFLP |
Liang, 2004 [34] | 9 | China/Asian | 95/188/100 | LSCC | 204/462/221 | PB | PCR-RFLP |
China/Asian | 64/127/74 | LA | 204/462/221 | PB | PCR–RFLP | ||
China/Asian | 25/50/24 | NSCLC | 204/462/221 | PB | PCR-RFLP | ||
Ghanshela, 2020 [35] | 7 | India/Asian | 24/60/16 | bladder cancer | 44/47/9 | HB | PCR-RFLP |
Gil, 2012 [36] | 7 | Poland/Caucasian | 16/67/50 | colorectal cancer | 16/58/26 | HB | PCR-RFLP |
Guo, 2008 [37] | 9 | China/Asian | 123/139/65 | ESCC | 162/322/128 | PB | PCR-RFLP |
Hall, 2007 [38] | 6 | Mixed/Caucasian | 21/71/75 | OSCC | 98/375/297 | HB | 5′ exonuclease assay |
Mixed/Caucasian | 15/42/54 | Pharynx SCC | 98/375/297 | HB | 5′ exonuclease assay | ||
Mixed/Caucasian | 39/134/146 | Laryngeal SCC | 98/375/297 | HB | 5′ exonuclease assay | ||
Mixed/Caucasian | 15/81/75 | ESCC | 125/451/398 | HB | 5′ exonuclease assay | ||
Han, 2012 [39] | 9 | Korea/Asian | 74/190/82 | Breast cancer | 103/169/89 | PB | Illumina GoldenGate |
Hansen, 2007 [40] | 7 | Denmark/Caucasian | 31/187/176 | Colorectal cancer | 90/359/339 | PB | Sequence dectection |
Hsieh, 2010 [41] | 6 | China/Asian | 33/87/38 | Leiomyoma | 35/84/37 | HB | PCR-RFLP |
Huang, 2007 [42] | 9 | China/Asian | 59/69/22 | Esophageal cancer | 210/160/32 | PB | PCR-RFLP |
China/Asian | 65/60/20 | Cardia gastric cancer | 112/55/13 | PB | PCR–RFLP | ||
China/Asian | 77/57/12 | Non-cardia gastric cancer | 112/55/13 | PB | PCR-RFLP | ||
Jelonek, 2010 [43] | 7 | Poland/Caucasian | 4/33/29 | Colon cancer | 17/70/46 | PB | PCR-RFLP |
Poland/Caucasian | 11/45/35 | Breast cancer | 48/168/142 | PB | PCR-RFLP | ||
Joshi, 2009 [44] | 8 | China/Asian | 66a/61 | Colon cancer | 91a/52 | PB | Taqman |
China/Asian | 100a/75 | Rectal cancer | 109a/94 | PB | Taqman | ||
Lawania, 2019 [45] | 6 | India/Asian | 82/59/4 | Lung cancer | 109/49/4 | PB | PCR-RFLP |
Liu, 2007 [46] | 8 | China/Asian | 50/35/11 | Esophageal cancer | 38/47/11 | PB | PCR-RFLP |
Miller, 2006 [47] | 8 | USA/Caucasian | 97/352/437 | Skin BCC | 101/340/355 | PB | PCR-RFLP |
USA/Caucasian | 74/277/331 | Skin SCC | 101/340/355 | PB | PCR-RFLP | ||
Palli, 2010 [48] | 7 | Italy/Caucasian | 35/115/134 | Gastric cancer | 59/215/249 | PB | Taqman |
Pan, 2009 [49] | 8 | USA/Caucasian | 35/166/179 | Esophageal cancer | 88/219/151 | PB | PCR-RFLP |
Park, 2002 [9] | 9 | Korea/Asian | 60/160/45 | Lung cancer | 38/101/46 | PB | PCR-RFLP |
Paszkowska, 2013 [50] | 6 | Poland/Caucasian | 78/294/306 | Melanoma | 93/255/240 | PB | Taqman |
Pesz, 2014 [51] | 6 | Poland/Caucasian | 7/53/38 | Skin BCC | 16/58/26 | PB | PCR-RFLP |
Popanda, 2004 [7] | 5 | Germany/Caucasian | 29/85/90 | LA | 46/213/198 | HB | Rapid capillary PCR |
Qian, 2011 [52] | 9 | China/Asian | 163/272/146 | NSCLC | 131/301/171 | PB | Taqman |
China/Asian | 86/131/68 | LSCC | 131/301/171 | PB | Taqman | ||
China/Asian | 53/114/62 | LA | 131/301/171 | PB | Taqman | ||
Raaschou, 2008 [53] | 7 | Denmark/Caucasian | 53/190/184 | Lung cancer | 90/355/335 | PB | Taqman |
Rafiq, 2016 [54] | 7 | India/Asian | 181/170/99 | ESCC | 223/189/38 | HB | PCR-RFLP |
Sakoda, 2012 [11] | 8 | USA/Caucasian | 71/326/320 | Lung cancer | 166/621/622 | PB | GoldenGate/TaqMan |
Tang, 2011 [55] | 7 | China/Asian | 17/62/25 | ALL | 52/74/43 | PB | MALDI-TOF-MS |
Tao, 2018 [56] | 6 | China/Asian | 111/197/85 | Neuroblastoma | 191/432/189 | HB | Taqman |
Vogel, 2005 [57] | 7 | Denmark/Caucasian | 32107/117 | Lung cancer | 23/98/148 | PB | Taqman |
Weiss, 2005 [58] | 8 | USA/Mixed | 29/147/195 | Endometrial cancer | 44/191/185 | PB | SNaPshot |
Wu, 2003 [59] | 9 | USA/others | 20/13/17 | Lung cancer | 9/19/19 | PB | PCR-RFLP |
USA/African | 15/30/36 | lung cancer | 7/26/34 | PB | PCR–RFLP | ||
Xie, 2007 [60] | 7 | China/Asian | 15/50/37 | HCC | 67/144/82 | PB | PCR-RFLP |
Zeng, 2013 [61] | 8 | China/Asian | 29/73/37 | Lung cancer | 29/73/31 | PB | PCR-RFLP |
Zhang, 2006 [62] | 7 | China/Asian | 91/82/33 | Esophageal cancer | 66/96/44 | HB | PCR-RFLP |
Zhao, 2018 [63] | 8 | China/Asian | 22/45/22 | Ovarian cancer | 108/165/83 | PB | Taqman |
Zhen, 2012 [64] | 9 | China/Asian | 107/145/99 | Esophageal cancer | 159/188/53 | PB | PCR--RFLP |
Zhu, 2015 [65] | 8 | China/Asian | 78/111/109 | Breast cancer | 85/136/77 | PB | Sequenom MassArray |
Zhu, 2018 [66] | 7 | China/Asian | 30/72/42 | Wilms tumor | 124/281/126 | PB | Taqman |
Zhu, 2005 [67] | 7 | China/Asian | 84/133/93 | Lung cancer | 72/180/89 | HB | PCR-RFLP |
Zhu, 2008 [68] | 8 | China/Asian | 69/69/50 | ESCC | 63/88/52 | PB | PCR-RFLP |
Zienolddiny, 2006 [6] | 8 | Norway/Caucasian | 30/88/130 | NSCLC | 37/125/114 | PB | Taqman |